Use of a German longitudinal prescription database (LRx) in pharmacoepidemiology;Einsatz einer deutschen longitudinalen verschreibungsdatenbank (LRx) in der pharmakoepidemiologie

GMS German Medical Science

Volumn 13, Issue , 2015, Pages

  Richter, Hartmut ^a   Dombrowski, Silvia ^a   Hamer, Hajo ^b   Hadji, Peyman ^c   Kostev, Karel ^d  

^a IQVIA   (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Department of Women’s Health North West Hospital ^*  (Germany)

^d FRESENIUS UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

Database; Epidemiology; LRx

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; INSULIN;

COMPARATIVE STUDY; DIABETES MELLITUS; EPILEPSY; FACTUAL DATABASE; GERMANY; HUMAN; INCIDENCE; INSULIN INFUSION; OSTEOPOROSIS; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PREVALENCE; STATISTICS AND NUMERICAL DATA;

ANTICONVULSANTS; DATABASES, FACTUAL; DIABETES MELLITUS; DRUG PRESCRIPTIONS; EPILEPSY; GERMANY; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; INSULIN INFUSION SYSTEMS; OSTEOPOROSIS; PHARMACOEPIDEMIOLOGY; PREVALENCE;

EID: 84941101520     PISSN: 16123174     EISSN: 16123174     Source Type: Journal    
DOI: 10.3205/000218     Document Type: Review

References (31)

1. Becher H, Kostev K, Schröder-Bernhardi D. Validity and representativeness of the "Disease Analyzer" patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther. 2009 Oct;47(10):617-26. DOI: 10.5414/CPP47617
2. Ahrens W, Hagemeier C, Mühlbauer B, Pigeot I, Püntmann I, Reineke A, Steinbach M, Timm J. Hospitalization rates of generic metoprolol compared with the original beta-blocker in an epidemiological database study. Pharmacoepidemiol Drug Saf. 2007; 16: 1298-1307. DOI: 10.1002/pds.1494
3. Grimmsmann T, Schwabe U, Himmel W. The influence of hospitalisation on drug prescription in primary care--a large-scale follow-up study. Eur J Clin Pharmacol. 2007 Aug;63(8):783-90. DOI: 10.1007/s00228-007-0325-1
4. Kostev K, Haas G, editors. Medical care in Germany: Epidemiology, health economics and outcome research with IMS patient databases. Göttingen: Optimus; 2011. ISBN 978-3- 941274-90-7. p. 3-6.
5. Kostev K, Rockel T, Rosenbauer J, Rathmann W. Risk factors for discontinuation of insulin pump therapy in pediatric and young adult patients. Prim Care Diabetes. 2014 Dec;8(4):346-51. DOI: 10.1016/j.pcd.2014.03.006
6. Hofer SE, Heidtmann B, Raile K, Fröhlich-Reiterer E, Lilienthal E, Berghaeuser MA, Holl RW; DPV-Science-Initiative; German working group for insulin pump treatment in pediatric patients. Discontinuation of insulin pump treatment in children, adolescents, and young adults. A multicenter analysis based on the DPV database in Germany and Austria. Pediatr Diabetes. 2010 Mar;11(2):116-21. DOI: 10.1111/j.1399- 5448.2009.00546.x
7. de Vries L, Grushka Y, Lebenthal Y, Shalitin S, Phillip M. Factors associated with increased risk of insulin pump discontinuation in pediatric patients with type 1 diabetes. Pediatr Diabetes. 2011 Aug;12(5):506-12. DOI: 10.1111/j.1399-5448.2010.00701.x
8. Kordonouri O, Klinghammer A, Lang EB, Grüters-Kieslich A, Grabert M, Holl RW. Thyroid autoimmunity in children and adolescents with type 1 diabetes: a multicenter survey. Diabetes Care. 2002 Aug;25(8):1346-50. DOI: 10.2337/diacare.25.8.1346
9. Ramakrishnan R, Appleton R. Study of prevalence of epilepsy in children with type 1 diabetes mellitus. Seizure. 2012 May;21(4):292-4. DOI: 10.1016/j.seizure.2012.01.003
10. Hadji P, Kostev K, Schröder-Bernhardi D, Ziller V. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany. Int J Clin Pharmacol Ther. 2012 Apr;50(4):281-9. DOI: 10.5414/CP201633
11. Falandry C, Campone M, Cartron G, Guerin D, Freyer G. Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. Eur J Cancer. 2010 Sep;46(13):2389-98. DOI: 10.1016/j.ejca.2010.04.031
12. Swanson G, Bergstrom K, Stump E, Miyahara T, Herfindal ET. Growth factor usage patterns and outcomes in the community setting: collection through a practice-based computerized clinical information system. J Clin Oncol. 2000 Apr;18(8):1764-70.
13. Wasem J, Bramlage P. Aktuelle Beispiele zur Fehlsteuerung von Kosten bei Therapien mit variabler Dauer durch die Verwendung von Defined Daily Doses. PharmEcon. 2009;7:47-54. DOI: 10.1007/bf03320758
14. Pfannkuche MS, Glaeske G, Neye H, Schöffski O, Hoffmann F. Kostenvergleiche für Arzneimittel auf der Basis von DDD im Rahmen der Vertragsärztlichen Versorgung [Advantages and limitations of the DDD system in the context of the German statutory health insurance system]. Gesundh ökon Qual manag. 2009;14(7):17-23. DOI: 10.1055/s-2008-1027735
15. Hamer HM, Dodel R, Strzelczyk A, Balzer-Geldsetzer M, Reese JP, Schöffski O, Graf W, Schwab S, Knake S, Oertel WH, Rosenow F, Kostev K. Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany--a nationwide population-based study in children and adults. J Neurol. 2012 Nov;259(11):2376-84. DOI: 10.1007/s00415-012-6509-3
16. Johannessen Landmark C, Larsson PG, Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders--a population-based study of prescriptions. Epilepsy Res. 2009 Nov;87(1):31-9. DOI: 10.1016/j.eplepsyres.2009.07.005
17. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jönsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen HC, Stovner LJ, Vallat JM, Van den Bergh P, den Bergh PV, van Os J, Vos P, Xu W, Wittchen HU, Jönsson B, Olesen J; CDBE2010Study Group. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011 Oct;21(10):718-79. DOI: 10.1016/j.euroneuro.2011.08.008
18. Forsgren L, Beghi E, Oun A, Sillanpää M. The epidemiology of epilepsy in Europe - a systematic review. Eur J Neurol. 2005 Apr;12(4):245-53. DOI: 10.1111/j.1468-1331.2004.00992.x
19. Hollingworth SA, Eadie MJ. Antiepileptic drugs in Australia: 2002-2007. Pharmacoepidemiol Drug Saf. 2010 Jan;19(1):82-9. DOI: 10.1002/pds.1871
20. Faught E, Richman J, Martin R, Funkhouser E, Foushee R, Kratt P, Kim Y, Clements K, Cohen N, Adoboe D, Knowlton R, Pisu M. Incidence and prevalence of epilepsy among older U.S. Medicare beneficiaries. Neurology. 2012 Feb;78(7):448-53. DOI: 10.1212/WNL.0b013e3182477edc
21. Dippel FW, Schneider T. Cost-comparison between different treatment regimens in diabetes mellitus in Germany based on long acting insulins. Diabetol Stoffwechsel. 2013;8(S01):P168. DOI: 10.1055/s-0033-1341828
22. Dippel FW, Schneider T, Schöffski O, Kleinfeld A, Ponzel R. Insulin glargin: eine kostengünstige Alternative im Vergleich zu NPHInsulin. Monitor Versorgungsforschung. 2009;6:31-5.
23. Dippel FW, Schneider T, Rosak C, Brüggenjürgen B. Behandlungskosten bei insulinpflichtigen Diabetikern unter Insulin Glargine versus Insulin Detemir - Ergebnisse einer repräsentativen Verordnungsdatenanalyse. Perfusion. 2009;6:194-9.
24. Gölz S, Dippel FW, Schneider T, Brüggenjürgen B. Behandlungskosten bei Diabetes mellitus: Vergleich von drei basalinsulinbasierten Therapieansätzen. Monitor Versorgungsforschung. 2011;5:46ff.
25. Willert T, Walker J, Schramm W. Regionale Analyse der medikamentösen Behandlungsprävalenz und Arzneimitteltherapie von Diabetes mellitus in Deutschland [Regional analysis of drug treatment prevalence and medication of diabetes mellitus in Germany]. Dtsch Med Wochenschr. 2012 Nov;137(46):2363-8. DOI: 10.1055/s-0032-1327273
26. Rathmann W, Scheidt-Nave C, Roden M, Herder C. Type 2 diabetes: prevalence and relevance of genetic and acquired factors for its prediction. Dtsch Arztebl Int. 2013 May;110(19):331-7. DOI: 10.3238/arztebl.2013.0331
27. Köster I, Huppertz E, Hauner H, Schubert I. Direct costs of diabetes mellitus in Germany - CoDiM 2000-2007. Exp Clin Endocrinol Diabetes. 2011 Jun;119(6):377-85. DOI: 10.1055/s- 0030-1269847
28. Ziller V, Kostev K, Kyvernitakis I, Boeckhoff J, Hadji P. Persistence and compliance of medications used in the treatment of osteoporosis--analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Ther. 2012 May;50(5):315-22. DOI: 10.5414/CP201632
29. Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther. 2006 Oct;28(10):1686-94. DOI: 10.1016/j.clinthera.2006.10.013
30. Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int. 2012 Jan;23(1):223-31. DOI: 10.1007/s00198-011-1535-z
31. Ziller V, Zimmermann SP, Kalder M, Ziller M, Seker-Pektas B, Hellmeyer L, Hadji P. Adherence and persistence in patients with severe osteoporosis treated with teriparatide. Curr Med Res Opin. 2010 Mar;26(3):675-81. DOI: 10.1185/03007990903538409